Sugi Predict

Sugi Predict / Targets / MATK

MATK

Megakaryocyte-associated tyrosine-protein kinase · P42679 · MATK on Sugi Atlas →

10,225 patent compounds predicted against MATK, 8,226 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Su-014813 Su-014813 (SCHEMBL902507) 1.00 3/20
Su-014813 Su-014813 (SCHEMBL1249521) 1.00 3/20
SCHEMBL264158 SCHEMBL264158 0.79 3/20
SCHEMBL1275642 SCHEMBL1275642 0.72 3/20
SCHEMBL422705 SCHEMBL422705 0.63 3/20
SCHEMBL425683 SCHEMBL425683 0.63 3/20
SCHEMBL1474409 SCHEMBL1474409 0.57 3/20
SCHEMBL1473979 SCHEMBL1473979 0.51 3/20
Sunitinib Sunitinib (SCHEMBL8081) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL8082) 1.00 2/20
SCHEMBL1363195 SCHEMBL1363195 1.00 2/20
SCHEMBL1364343 SCHEMBL1364343 1.00 2/20
Sunitinib Sunitinib (SCHEMBL18648) 0.92 2/20
SCHEMBL1362165 SCHEMBL1362165 0.90 2/20
SCHEMBL1361786 SCHEMBL1361786 0.89 2/20
SCHEMBL1362874 SCHEMBL1362874 0.87 2/20
Sunitinib Sunitinib (SCHEMBL1082191) 0.86 2/20
SCHEMBL1362588 SCHEMBL1362588 0.85 2/20
Sunitinib Sunitinib (SCHEMBL55459) 0.84 2/20
Sunitinib Sunitinib (SCHEMBL1258610) 0.84 2/20

Clinical trials — most relevant to MATK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study PHASE2/PHASE3COMPLETED
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer PHASE3COMPLETED
Protein Tyrosine Kinases (PTK) in Multiple Myeloma PHASE2COMPLETED
Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP PHASE1/PHASE2COMPLETED
A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients PHASE2COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML PHASE2COMPLETED
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma PHASE2COMPLETED
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia PHASE2RECRUITING
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis PHASE2NOT_YET_RECRUITING
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Study of Bone Marrow Samples From Patients With Acute Leukemia nanCOMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Cardiac Changes in Myeloproliferative Neoplasms nanUNKNOWN
Cutaneous JAK in Vitiligo and Acne Vulgaris. nanUNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. nanUNKNOWN
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MATK binder may also engage these)

ProteinNameSimilarity
P41242 — 1.000 P41242 →
P41243 — 0.995 P41243 →
SRMS Tyrosine-protein kinase Srms 0.993 landscape →
JAK3 Tyrosine-protein kinase JAK3 0.990 landscape →
Q63474 — 0.983 Q63474 →
O09127 — 0.983 O09127 →
Q64434 — 0.983 Q64434 →
PTK6 Protein-tyrosine kinase 6 0.983 landscape →
Q99ML2 — 0.982 Q99ML2 →
EPHB4 Ephrin type-B receptor 4 0.982 landscape →
Q8BYG9 — 0.982 Q8BYG9 →
Q6J9G1 — 0.982 Q6J9G1 →
Q03146 — 0.982 Q03146 →
P0C0K6 — 0.982 P0C0K6 →
Q62270 — 0.981 Q62270 →
TNK1 Non-receptor tyrosine-protein kinase TNK1 0.981 landscape →
TYK2 Non-receptor tyrosine-protein kinase TYK2 0.981 landscape →
Q922K9 — 0.980 Q922K9 →
P51839 — 0.980 P51839 →
P51840 — 0.980 P51840 →
DDR1 Epithelial discoidin domain-containing receptor 1 0.980 landscape →
Q62137 — 0.979 Q62137 →
CSF1R Macrophage colony-stimulating factor 1 receptor 0.979 landscape →
Q13308 — 0.979 Q13308 →
P55203 — 0.978 P55203 →
Q61288 — 0.978 Q61288 →
P42682 — 0.978 P42682 →
Q91ZR4 — 0.978 Q91ZR4 →
P80203 — 0.978 P80203 →
MKNK1 MAP kinase-interacting serine/threonine-protein kinase 1 0.978 landscape →